Derivatives of 1,2,3,4-tetrahydro-9-acridinamine

Abstract: Novel prodrugs or depot derivatives of 1,2,3,4-tetrahydro-9-acridinamine of formula I are described, as well as methods for the preparation and pharmaceutical compositions of same, which are useful as analgesic agents for the treatment of pain, as sleep aids and as agents for treating the symptoms of senile dementia, Alzheimer's disease, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, or similar conditions of cerebral insufficiency characterized by decreased cerebral acetylcholine production or release.

Description: The present invention relates to novel derivatives of 1,2,3,4-tetrahydro-9-acridinamine useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to their use for the preparation of pharmaceutical compositions for treating the symptoms of cognitive decline in elderly patients. More particularly, the novel compounds of the present invention are derivatives of 1,2,3,4-tetrahydro-9-acridinamine which are useful in treating the above symptoms. Disorders of cognition are generally characterized by symptoms of forgetfulness, confusion, memory loss, attentional deficits and/or, in some cases, affective disturbances. These symptoms may arise as a result of the general aging process and/or from organic brain disease, cerebrovascular disease, head injury or developmental or genetic defects. The general decrease in cognitive function which accompanies the aging process is well accepted. The same phenomenon has been observed and documented in many lower mammals, including those routinely employed in pharmacological testing programs for screening and predicting usefulness for particular drugs in higher animals, including humans. Although disorders of cognition often accompany the general aging process, presenile and senile primary degenerative dementia are the most common accepted causes of mental deterioration in the elderly. It has been estimated that at least ten percent of persons over sixty years of age will eventually suffer severe mental deterioration. A much larger number will experience cognitive decline of sufficient severity to impede their activities. Many of the symptoms of cognitive disorders, especially impaired memory, are associated with decreased acetylcholine synthesis and the impairment of cholinoreceptive neurons. In the hippocampus and cerebral cortex of patients suffering from primary degenerative dementia for example, the level of the enzyme choline acetyltransferase (CAT) can be reduced as much as ninety percent (see Davies, P., et al, The Lancet , 2, page 1403 (1976); Perry, E. K., et al, Journal of Neurological Sciences , 34, pages 247 to 265 (1977); and white, P., et al, The Lancet , 1, pages 668 to 670 (1977)). Since CAT catalyzes the synthesis of acetylcholine from its precursors choline and acetyl coenzyme A, the loss of CAT reflects the loss of cholinergic or acetylcholine-releasing nerve endings in the hippocampus and cerebral cortex. There is abundant evidence that cholinergic terminals in the hippocampus are critically important for memory formation. The cholinergic hypothesis suggests that drugs which restore acetylcholine levels or cholinergic function (i.e., cholinomimetic) are effective in correcting this deficit in neurotransmitter chemical and provide treatment of the memory impairment symptom of cerebral insufficiency. Considerable biochemical, pharmacological, and electrophysiological evidence supports the hypothesis that deficits in the cholinergic system underlie geriatric cognitive dysfunction (Peterson, C. and Gibson, G. E., Neurobiology of Aging , 4, pages 25 to 30 (1983)). Aged humans and nonhuman primates with decreased cognition show improved memory when they are treated, for example, with acetylcholinesterase inhibitors such as 1,2,3,4-tetrahydro-9-acridinamine and physostigmine. These agents increase the available supply of synaptic acetylcholine by inhibiting its hydrolysis. 1,2,3,4-Tetrahydro-9-acridinamine (tacrine; THA) has been shown to be useful in the long-term palliative treatment of patients with Alzheimer's disease (Summers, W. K., et al, The New England Journal of Medicine , 315 , pages 1241 to 1245 (1986)). The results indicated that when the dose of tacrine was increased up to 200 mg per day the clinical response improved dramatically. However, toxic side effects also were noted when large doses of tacrine were used. Thus, there is a need to administer a therapeutically effective amount of tacrine over a prolonged period of time to a patient without the concomitant undesirable toxic side effects. Ideally, if a drug is delivered to the target area in a controlled amount, therapy should be maximized and toxic side effects minimized. One method of controlling the release of a drug is to derivatize as a prodrug or to localize the drug in some biological depot or site within the organism with subsequent slow release of the drug in a therapeutically effective quantity over an extended period of time. Various biologically active agents have been modified chemically to form prodrugs or depot derivatives. The derivative is then administered to a patient, localized in a biological depot and subsequently biotransformed in vivo into the active agent over an extended period of time. A prodrug or a depot derivative has several advantages, one of which is that the patient is exposed to less total active drug in any given period of time which minimizes or eliminates local or systemic side effects. Additionally, there is a decrease in the frequency with which the patient has to take the drug. This is particularly important in the case of a patient suffering from Alzheimer's disease where patient compliance is a problem. However, the chemically altered prodrug or depot derivative may result in a drug with a different pharmacological profile than that found in the parent drug. We have found unexpectedly that certain 9-substituted amino derivatives of tacrine act as prodrugs or depot agents and release tacrine in vivo over a prolonged period of time and are thus useful in the long-term treatment of patients with Alzheimer's disease. Compounds of formula I showing alkyl moieties with up to 7 carbon atoms are disclosed in EP-A-0319429. However, this document does not disclose the unexpected high effects obtained from compounds having a higher alkyl chain for R with more than seven and up to 20 carbon atoms and that especially these long chain radicals form ideal prodrugs of depot agents for tacrine and release tacrine in vivo over a long period of time. Accordingly, the present invention is a compound of Formula I wherein R is alkyl of from more than 7 up to twenty carbon atoms or a pharmaceutically acceptable acid addition salt thereof. As prodrugs or depot derivatives of 1,2,3,4-tetrahydro-9-acridinamine the compounds of Formula I are useful as analgesic agents for the treatment of pain in mammals including man, as sleep aids and as agents for treating the symptoms of senile dementia, Alzheimer's disease, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania or similar conditions of cerebral insufficiency characterized by decreased cerebral acetylcholine production or release. A still further embodiment of the present invention is a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier. A still further embodiment is the use of a compound of Claims 1 to 3 for the preparation of a pharmaceutical composition for treating the symptoms of cognitive decline in elderly patients, Alzheimer's disease, senile dementia, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, or similar conditions of cerebral insufficiency. Finally, the present invention is directed to methods for production of a compound of Formula I. DETAILED DESCRIPTION OF THE INVENTION In the compounds of Formula I, the term "alkyl" means a straight or branched hydrocarbon radical having more than 7 up to twenty carbon atoms and includes, for example n-octyl, n-nonyl, n-decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl or eicodecyl. "Halogen" is fluorine, chlorine, bromine, or iodine. For purposes of the present invention a "prodrug" refers to a compound of Formula I which is biotransformed gradually into 1,2,3,4-tetrahydro-9-acridinamine in a mammal. For purposes of the present invention, a "depot derivative" refers to a compound of Formula I which is deposited in a body tissue or body cavity for a prolonged period of time, said compound serving as a reservoir which gradually releases 1,2,3,4-tetrahydro-9-acridinamine at a controlled rate over an extended length of release time in a mammal. Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge, S. M., et al, "Pharmaceutical Salts," Journal of Pharmaceutical Science , Vol. 66 , pages 1-19 (1977)). The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free bases for purposes of the present invention. Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain of the compounds of the present invention possess asymmetric carbon atoms (optical centers); the racemates as well as the individual enantiomers are intended to be encompassed within the scope of the present invention. A preferred compound of Formula I is one wherein R is alkyl of from more than 7 up to twenty carbon atoms. A more preferred compound of Formula I is one wherein R is alkyl of from more than 7 up to fifteen carbon atoms. Particularly valuable is: N -(1,2,3,4-tetrahydro-9-acridinyl)decanamide or a pharmaceutically acceptable acid addition salt thereof. The ability of a compound of Formula I to act as a prodrug or a depot agent and release tacrine in vivo over a prolonged period of time was demonstrated, for example, using the following assay procedure: ASSAY PROCEDURE : A compound of Formula I was suspended in a 50:50 mixture of castor oil and benzyl benzoate at a concentration of 100 mg/ml. A single 300 mg/kg nonsterile dose of the selected compound of Formula I was administered intramuscularly into the left gluteal muscle of three male Wistar rats. The depot dose was estimated to be approximately 30 times the single dose of tacrine given to rats when calculated on a molar basis. Blood samples were collected predose and 1, 3, 7, 11 and 14 days following drug administration. All blood samples were collected from the orbital sinus following ether anesthesia. Plasma was harvested and analyzed for tacrine. The data in Table I shows the ability of representative compounds of Formula I to release tacrine in vivo over a prolonged period of time. TACRINE PLASMA CONCENTRATION-TIME DATA FOLLOWING ADMINISTRATION OF A COMPOUND OF FORMULA I Example Number Compound Tacrine Plasma Concentrations (ng/ml) RAT Day 1 Day 3 Day 7 Day 11 Day 14 1 N-(1,2,3,4-Tetrahydro-9-acridinyl)decanamide 1 1.66 0.00 3.51 3.59 1.48 2 24.40 2.20 4.60 6.01 3.56 3 0.00 0.00 0.00 0.00 Mean 8.69 0.73 4.06 3.20 1.68 A compound of Formula I wherein R is alkyl of from more than 7 up to twenty carbon atoms or a pharmaceutically acceptable acid addition salt thereof, may be prepared by reacting a compound of Formula II with a compound of Formula III wherein Hal is halogen, preferably chlorine or bromine, and R is as defined above in the presence of a base and solvent such as, for example, triethylamine and chloroform, n-butyllithium and tetrahydrofuran and the like at about 0°C to about the reflux temperature of the solvent to afford a compound of Formula I. Additionally, a compound of Formula I may be prepared by reacting a compound of Formula II with a compound of Formula IV HO 2 C-CH 2 R wherein R is as defined above in the presence of a coupling reagent such as, for example, 1,3-dicyclohexylcarbodiimide (DCC), bis(2-oxo-3-oxazolidinyl)-phosphinic chloride (BOP-Cl) and the like, and if desired 1-hydroxybenzotriazole (HOBt) in the presence of a solvent such as, for example, methylene chloride, dimethylformamide, dioxane, tetrahydrofuran and the like at about -5°C to about 25°C to afford a compound of Formula I a . Other coupling methods that can be employed in preparing the compounds of Formula I a are discussed in "The Peptides. Analysis, Synthesis, Biology", Gross, E., and Meienhofer, J., eds, Academic Press, New York, New York, Volume 1, 1979. Compounds of Formula III and Formula IV are either known or capable of being prepared by methods known in the art. The compound of Formula II is described in Petrow, V., Journal of the Chemical Society , pages 634 to 637 (1947). The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I. Preferably the compounds of the present invention are administered orally, intramuscularly or subcutaneously. For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration. For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 7000 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents. In therapeutic use as prodrugs or depot derivatives of 1,2,3,4-tetrahydro-9-acridinamine the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg per kilogram daily. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. The following nonlimiting example illustrates the inventors' preferred methods for preparing the compounds of the invention. EXAMPLE 1 N -(1,2,3,4-Tetrahydro-9-acridinyl)decanamide . Freshly distilled decanoyl chloride, 5.18 g (0.029 mol), is slowly added to a mixture of 2.94 g (0.029 mol) of triethylamine and 5.82 g (0.029 mol) of 1,2,3,4-tetrahydro-9-acridinamine (Petrow, V., Journal of the Chemical Society , pages 634 to 637 (1947)) in 150 ml of chloroform. The mixture is heated at reflux for two hours, cooled to room temperature, filtered, and the filtrate evaporated to afford, after repeated washing with diethyl ether, 1.67 g of N -(1,3,4,5-tetrahydro-9-acridinyl)decanamide as a yellow solid; mp 123-126°C.

Claims: A compound of Formula I wherein R is alkyl of from more than seven up to twenty carbon atoms or a pharmaceutically acceptable acid addition salt thereof. A compound according to Claim 1, in which R is alkyl of from more than seven up to fifteen carbon atoms. A compound according to Claim 1 and 2, and being N -(1,2,3,4- tetrahydro-9-acridinyl)decanamide. A method of preparing a compound of Formula I according to Claims 1 to 3: wherein R is alkyl of from more than seven up to twenty carbon atoms or a pharmaceutically acceptable acid addition salt thereof, comprising reacting a compound of Formula II with a compound of Formula III wherein Hal is halogen and R is as defined above in the presence of a base and a solvent at about 0°C to about the reflux temperature of the solvent to afford a compound of Formula I and, if desired, converting a compound of Formula I to a corresponding pharmaceutically acceptable acid addition salt by conventional means and, if so desired, converting the corresponding pharmaceutically acceptable acid addition salt to a compound of Formula I by conventional means. Use of a compound of Claims 1 to 3 for the preparation of a pharmaceutical composition for treating the symptoms of cognitive decline in elderly patients, Alzheimer's disease, senile dementia, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, or similar conditions of cerebral insufficiency. Use of a compound of claims 1 to 3 for the preparation of a pharmaceutical composition useful as analgesic agents for the treatment of pain and as sleep aids. A pharmaceutical composition comprising a compound of Claims 1 to 3 and a pharmaceutically acceptable carrier. A pharmaceutical composition as claimed in Claim 7 suitable for oral administration. A pharmaceutical composition as claimed in Claim 7 suitable for parenteral administration A pharmaceutical composition as claimed in Claim 9 suitable for intramuscular and subcutaneous administration.

Inventors: GRANGER COLIN, KESTER JEFFREY ALAN, MOOS WALTER HAMILTON, THOMAS ANTHONY JEROME, GRANGER, COLIN, KESTER, JEFFREY ALAN, MOOS, WALTER HAMILTON, THOMAS, ANTHONY JEROME
Applicants: WARNER LAMBERT CO, WARNER-LAMBERT COMPANY
Application year: 1990
Main classification: C07D219
IPC codes: C07D219, A61K31, A61P25